You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

skb264

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • SKB264
  • +4 more
  • (no location specified)
Oct 7, 2023

Solid Tumor Trial (SKB264, Pembrolizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Dec 8, 2022

Selected Subjects With Advanced Solid Tumors Trial in Guangzhou (SKB264)

Not yet recruiting
  • Selected Subjects With Advanced Solid Tumors
  • SKB264
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Nov 18, 2022

NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • SKB264
  • +3 more
  • (no location specified)
May 23, 2023

NSCLC Trial in Guangzhou (SKB264, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • SKB264
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University, Cancer Center
Apr 14, 2023

Triple-negative Breast Cancer Trial in Changsha, Nanjing (SKB264, KL-A167)

Not yet recruiting
  • Triple-negative Breast Cancer
  • Changsha, Hunan, China
  • +1 more
Jun 30, 2022

NSCLC Trial in Guangzhou (SKB264, KL-A167, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • SKB264
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 24, 2022

Triple Negative Breast Cancer Trial (SKB264)

Not yet recruiting
  • Triple Negative Breast Cancer
  • SKB264
  • (no location specified)
Apr 20, 2022